Month: June 2020

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.“We believe our addition to the Russell 3000 and 2000 Indexes validates the significant progress we have made in advancing our ongoing clinical programs in X-linked retinitis pigmentosa and achromatopsia,” said Sue Washer, President and CEO of AGTC. “In 2020, we already announced positive data and completed enrollment in our XLRP trial, reported encouraging...

PHOENIX, Ariz., June 24, 2020 (GLOBE NEWSWIRE) — Tombstone Exploration Corporation (OTCQB: TMBXF), a fully reporting U.S. based mining company, is pleased to announce in combination with Goldrock Resources Inc. and the Bonanza Mining Company that the construction phase is moving smoothly and on track for the complete build out of the heap leach pad and pond at the Bonanza Harquahala Gold Mine in La Paz County, Arizona.The Bonanza Mine property includes the Harquahala and Golden Eagle mines, located approximately eight miles south of Salome, Arizona. The project totals 2,656 acres and has significant underground workings. Once leaching has started, bi-weekly delivery of the carbon to a designated gold processing facility is expected. Based on past metallurgical testing, production is budgeted at 23,000 ounces of gold or more for...

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it received early notification from the U.S. Food and Drug Administration (FDA) that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19. Losmapimod is an orally available selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.The LOSVID trial is a Phase 3, international, multicenter trial designed to assess the safety and efficacy of a 15 mg twice per day oral dose of losmapimod compared to placebo for 14 days on top of standard of care in approximately 400 patients hospitalized...

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Sprott Inc. (“Sprott” or the “Company”) (TSX: SII) announced today that its common shares have been approved for listing on the New York Stock Exchange (“NYSE”). The Company expects its common shares will commence trading on the NYSE as of market open on June 29, 2020 under the ticker symbol “SII”.Peter Grosskopf, Chief Executive Officer of Sprott, commented, “Listing on the NYSE is a significant milestone for Sprott and a natural next step in the evolution of the company. We are pleased to offer our shareholders the ability to trade in U.S. dollars and the expected increase in liquidity. With the current surge in global interest in precious metals investments, we believe this is an excellent time for the NYSE listing and look forward to introducing Sprott to a new and larger investor base.”Additional...

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Loncor Resources Inc. (“Loncor” or the “Company“) (TSX: “LN”; OTCQB: “LONCF”) announces that its 76.29%-owned subsidiary, Adumbi Mining SARL (“Adumbi Mining”), has entered into a joint venture agreement (the “New Barrick JV“) with Barrick Gold (DRC) Limited for two exploitation permits held by Adumbi Mining (the “JV Permits”) covering ground contiguous to the Company’s Imva area within the Ngayu gold belt in the northeast of the Democratic Republic of the Congo (“DRC”). The purpose of the New Barrick JV is to conduct exploration on the JV Permit properties to evaluate possible development and mining of such properties.The Ngayu gold belt lies approximately 220 kilometres from the Kibali gold mine, operated by Barrick (TSX: “ABX”;...

TORONTO, June 24, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that the Company has completed shipping the second 10,000 purchase order of COVID-19 test kits (the “PO”) to a Canadian based mining company with operations worldwide.The total gross sales amount is approximately $500,000 CDN, excluding shipping fees. Datametrex anticipates that it has little or no upfront costs associated with the sale of these test kits.  All of the items are shipped from manufacturers to the purchaser’s mine operating sites in Ontario and Quebec.Under the terms of the PO, Datametrex provides them with an initial 10,000 units of the COVID-19 qPCR Detection Kits manufactured by 1drop Inc. (“1drop”), 10,000 Universal Transport...

FRISCO, Texas, June 24, 2020 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark”) (OTC: ZEST), announced that its wholly owned subsidiary, White River SPV 2 LLC, appeared virtually before the United States Bankruptcy Court for the Southern District of Texas, Houston Division on June 18, 2020 and completed the acquisition of certain assets located in Mississippi and Louisiana from SN TMS, LLC, a subsidiary of Sanchez Energy Corporation (“Sanchez Energy”), in conjunction with Chapter 11 Case No. 19-34508 (MI). The all-cash transaction, paid from existing cash on hand, includes 6 wellbores and additional leasehold acreage including a participation option for deep drilling rights on various acreage with proved reserves. This transaction follows Ecoark’s announcement made on June 11, 2020 regarding the acquisition of 262 total...

NEWTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating XPOVIO in patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) were published online in The Lancet Haematology. The SADAL study evaluated selinexor, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound for the treatment of adult patients with RR DLBCL, not otherwise specified, who have received at least two prior therapies.  “The clinical outcomes for patients with heavily pretreated relapsed or refractory DLBCL are typically very poor, and hence results from the multinational Phase 2b SADAL study are noteworthy,” said...